Pharmacogenetics of the arylamine N-acetyltransferases

Pharmacogenomics Journal

Volumn 2, Issue 1, 2002, Pages 30-42

  Butcher, N J ^a,b   Boukouvala, S ^c   Sim, E ^c   Minchin, R F ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acetylation; Arylamine; N acetyltransferase; NAT; Polymorphism

Indexed keywords

AMONAFIDE; ARYLAMINE ACETYLTRANSFERASE; CHEMICAL COMPOUND; CIGARETTE SMOKE; COTRIMOXAZOLE; DAPSONE; DRUG; ENDRALAZINE; HYDRALAZINE; ISONIAZID; NITRAZEPAM; PHENELZINE; PHENYLENEDIAMINE; PHENYTOIN; PROCAINAMIDE; RIFAMPICIN; SALAZOSULFAPYRIDINE; SULFADIMIDINE; SULFAMETHOXAZOLE; SULFONAMIDE;

ADVERSE DRUG REACTION; CARCINOGENESIS; CONTACT DERMATITIS; CONTROLLED STUDY; DETOXIFICATION; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; EXCRETION; EXHAUST GAS; EXPOSURE; FOOD; GENETIC SUSCEPTIBILITY; HUMAN; LEUKOPENIA; LIVER TOXICITY; METABOLISM; METABOLITE; MOLECULAR GENETICS; NAUSEA AND VOMITING; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXICITY;

ALLELES; AMINO ACID SEQUENCE; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; HUMANS; MOLECULAR SEQUENCE DATA; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY; TERMINOLOGY;

EID: 0036361175     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500053     Document Type: Article

References (141)

1. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases
2. Metabolic activation of mutagenic heterocyclic aromatic amines from protein pyrolysates
3. N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells
4. Human N-acetylation of benzidine: Role of NAT1 and NAT2
5. Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation
6. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization, and functional expression
7. Isolation and mapping of a cosmid clone containing the human NAT2 gene
8. Chromosomal localization of human genes for arylamine N-acetyl-transferase
9. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer
10. Molecular abnormalities associated with secretory carcinomas of the breast
11. Loss of heterozygosity on 8p in prostate cancer implicates a role for dematin in tumor progression
12. Allelic loss on chromosome arm 8p: Analysis of sporadic epithelial ovarian tumors
13. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer
14. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver
15. Nomenclature for N-acetyltransferases
16. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations
17. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe
18. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas
19. Structure of arylamine N-acetyltransferase reveals a catalytic triad
20. On the active site of liver acetyl-CoA. Arylamine N-acetyltransferase from rapid acetylator rabbits (III/J)
21. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia call. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2
22. Lessons from the rifamycin biosynthetic gene cluster
23. Arylamine N-acetyltransferases of mice, men and microorganisms
24. Update on consensus arylamine N-acetyltransferase gene nomenclature
25. Construction of Syrian hamster lines congenic at the polymorphic acetyl-transferase locus (NAT2): Acetylator genotype-dependent N- and O-acetylation of arylamine carcinogens
26. Slow acetylation in mice is caused by a labile and catalytically impaired mutant N-acetyltransferase (NAT2 9)
27. Longitudinal distribution of arylamine N-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine
28. Effect of streptolysin-O-on rat hepatic acetyl coenzyme-A: Arylamine N-acetyltransferase and cytochrome P-450 2B 1/2 activities ex vivo
29. Purification and biochemical properties of an N-hydroxyarylamine O-acetyltransferase from Escherichia coli
30. Acetylation of procainamide and isoniazid by a rat liver-N-acetyl-transferase
31. Acetyl-coenzyme A: Arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate
32. Eubacterial arylamine N-acetyltransferases-identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues
33. Identification and functional characterisation of arylamine N-acetyltransferase in eubacteria: Evidence for highly selective acetylation of 5-aminocisalicylic acid
34. Evidence for arylamine N-acetyltransferase activity in the bacterium Helicobacter pylori
35. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases
36. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours
37. Molecular genetic basis of rapid and slow acetylation in mice
38. Arylamine N-acetyltransferase in Balb/c mice: Identification of a novel mouse isoenzyme by cloning and expression in vitro
39. Cloned mouse N-acetyltransferases: Enzymatic properties of expressed Nat-1 and Nat-2 gene products
40. Substrate selectivity of mouse N-acetyltransferases 1, 2, and 3 expressed in COS-1 cells
41. Chromosome mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: Identification of a novel upstream noncoding exon for murine Nat2
42. Linkage of Nat and Es-1 in the mouse and development of strains congenic for N-acetyltransferase
43. Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: Functional characterization of the activation and deactivation of carcinogens
44. N-acetylation pharmacogenetics: A gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits
45. Cloning, expression, and functional characterization of rapid and slow acetylator polymorphic N-acetyl-transferase encoding genes of the Syrian hamster
46. Acetylator phenotype-dependent and -independent expression of arylamine N-acetyltransferase isozymes in rapid and slow acetylator inbred rat liver
47. Nucleotide sequence of a full-length cDNA for arylamine N-acetyltransferase from rabbit liver
48. Deficiency of cytosolic arylamine N-acetylation in the domestic cat and wild felids caused by the presence of a single NAT1-like gene
49. Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes
50. Molecular mechanism of slow acetylation of drugs and carcinogens in humans
51. Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes
52. Human acetyltransferase polymorphisms
53. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans
54. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity
55. Genotyping human polymorphic arylamine N-acetyltransferase: Identification of new slow allotypic variants
56. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
57. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver
58. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli
59. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases
60. Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli
61. Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis
62. Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype
63. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: Effects of 7 specific NAT2 nucleic acid substitutions
64. Molecular genetics of human polymorphic N-acetyltransferase: Enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes
65. N-acetyltransferase
66. Molecular mechanisms of genetic polymorphisms of drug metabolism
67. Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver
68. Characterization of human lymphocyte N-acetyltransferase and its relationship to the isoniazid acetylator polymorphism
69. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes
70. Kinetics of acetyl CoA: Arylamine N-acetyltransferase from rapid and slow acetylator human liver
71. Arylamine N-acetyltransferase in human red blood cells
72. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood
73. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus
74. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: Association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue
75. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder
76. Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis
77. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): The identification of two novel allelic variants
78. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer
79. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1)
80. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1
81. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk
82. Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction-restriction fragment-single strand conformation polymorphism assay
83. Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population
84. Genetically determined variability in acetylation and oxidation. Therapeutic implications
85. Survey of the human acetylator polymorphism in spontaneous disorders
86. Immunoperoxidase detection of 4-aminobiphenyl- and polycyclic aromatic hydrocarbons-DNA adducts in induced sputum of smokers and nonsmokers
87. Human exposure to carcinogenic heterocyclic amines and their mutational fingerprints in experimental animals
88. An international literature survey of 'IARC Group I carcinogens' reported in mainstream cigarette smoke
89. Molecular epidemiology studies on occupational and environmental exposure to mutagens and carcinogens, 1997-1999
90. Non-Hodgkin's lymphoma and occupational exposure to chemicals in Canada
91. Benzidine-DNA adduct levels in human peripheral white blood cells significantly correlate with levels in exfoliated urothelial cells
92. N-acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark
93. Aromatic amine acetyltransferase as a marker for colorectal cancer: Environmental and demographic associations
94. Acetylation phenotype in colorectal carcinoma
95. Role of aromatic amine acetyltransferase in human colorectal cancer
96. N-acetyltransferase polymorphisms and colorectal cancer: A HuGE review
97. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer
98. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England
99. Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells
100. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps
101. Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP) in rat extrahepatic tissues
102. Metabolic activation and DNA adduct detection of PhIP in dogs, rats, and humans in relation to urinary bladder and colon carcinogenesis
103. The ability of two cooked food mutagens to induce aberrant crypt foci in mice
104. Association between acetylator genotype and 2-amino-1-methyl-6-phenyl-imidazo[4, 5-b]pyridine (PhIP) DNA adduct formation in colon and prostate of inbred Fischer 344 and Wistar Kyoto rats
105. Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease
106. Variability and validity of polymorphism association studies in Parkinson's disease
107. Biochemical, molecular genetic and ecogenetic studies of polymorphic arylamine N-acetyltransferase (NAT2) in the brain
108. Enzymatische inaktivierung von isonicotinsaurehydrazid im menschlichen und tierischen organismus
109. Acetylator phenotype and the antihypertensive response to hydralazine
110. Hydralazine kinetics after single and repeated oral doses
111. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism
112. Clinical pharmacokinetics of sulphasalazine
113. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
114. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection
115. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects
116. Development of dapsone toxicity in patients with inflammatory dermatoses: Activity of acetylation and hydroxylation of dapsone as risk factors
117. Paradoxical relationship between acetylator phenotype and amonafide toxicity
118. Phase I study of amonafide dosing based on acetylator phenotype
119. Population pharmacodynamic study of amonafide: A Cancer and Leukemia Group B study
120. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender
121. Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: Increased expression results in isoniazid resistance
122. N-acetylation and N-formylation of carcinogenic arylamines and related compounds in dogs
123. Intestinal microflora enhances formation of DNA adducts following administration of 2-NF and 2-AAF
124. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level
125. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants
126. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism
127. Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine
128. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome
129. Phenytoin toxicity due to concomitant antituberculosis therapy
130. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity
131. The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children
132. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis
133. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis
134. Acetylation status is associated with serological changes but not clinically significant disease in patients receiving procainamide
135. Autoallergic reactions induced by procainamide
136. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus
137. Influence of acetylator phenotype on antidepressant effects of phenelzine
138. The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine
139. Acetylator phenotype in patients with p-phenylenediamine allergy